1. Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. Ma LJ, Corsa BA, Zhou J, Yang H, Li H, Tang YW, Babaev VR, Major AS, Linton MF, Fazio S, Hunley TE, Kon V, Fogo AB (2011) Am J Physiol Renal Physiol 300(5): F1203-13
    › Primary publication · 21367915 (PubMed) · PMC3094053 (PubMed Central)
  2. The spectrum of FSGS: does pathology matter? Fogo AB (2010) Nephrol Dial Transplant 25(4): 1034-6
    › Primary publication · 20083475 (PubMed)
  3. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Coppo R, Troyanov S, Camilla R, Hogg RJ, Cattran DC, Cook HT, Feehally J, Roberts IS, Amore A, Alpers CE, Barratt J, Berthoux F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator SN, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo AB, Geddes CC, Groene HJ, Haas M, Herzenberg AM, Hill PA, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Li LS, Li PK, Liu ZH, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2010) Kidney Int 77(10): 921-7
    › Primary publication · 20200498 (PubMed)
  4. The glomerulus--a view from the inside--the endothelial cell. Fogo AB, Kon V (2010) Int J Biochem Cell Biol 42(9): 1388-97
    › Primary publication · 20541032 (PubMed)
  5. Sulodexide ameliorates early but not late kidney disease in models of radiation nephropathy and diabetic nephropathy. Rossini M, Naito T, Yang H, Freeman M, Donnert E, Ma LJ, Dunn SR, Sharma K, Fogo AB (2010) Nephrol Dial Transplant 25(6): 1803-10
    › Primary publication · 20061322 (PubMed) · PMC2902889 (PubMed Central)
  6. Sirt1 activation protects the mouse renal medulla from oxidative injury. He W, Wang Y, Zhang MZ, You L, Davis LS, Fan H, Yang HC, Fogo AB, Zent R, Harris RC, Breyer MD, Hao CM (2010) J Clin Invest 120(4): 1056-68
    › Primary publication · 20335659 (PubMed) · PMC2846063 (PubMed Central)
  7. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Fogo AB, Bostad L, Svarstad E, Cook WJ, Moll S, Barbey F, Geldenhuys L, West M, Ferluga D, Vujkovac B, Howie AJ, Burns A, Reeve R, Waldek S, Noël LH, Grünfeld JP, Valbuena C, Oliveira JP, Müller J, Breunig F, Zhang X, Warnock DG, all members of the International Study Group of Fabry Nephropathy (ISGFN) (2010) Nephrol Dial Transplant 25(7): 2168-77
    › Primary publication · 19833663 (PubMed) · PMC2902894 (PubMed Central)
  8. Recurrent pauci-immune necrotizing crescentic glomerulonephritis in a kidney transplant patient. Schaefer HM, Langone A, Helderman JH, Fogo AB (2010) Am J Kidney Dis 55(3): 604-8
    › Primary publication · 19782451 (PubMed)
  9. Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Joy MS, Gipson DS, Powell L, MacHardy J, Jennette JC, Vento S, Pan C, Savin V, Eddy A, Fogo AB, Kopp JB, Cattran D, Trachtman H (2010) Am J Kidney Dis 55(1): 50-60
    › Primary publication · 19932542 (PubMed) · PMC2804955 (PubMed Central)
  10. Pathologic classification of diabetic nephropathy. Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, Ferrario F, Fogo AB, Haas M, de Heer E, Joh K, Noël LH, Radhakrishnan J, Seshan SV, Bajema IM, Bruijn JA, Renal Pathology Society (2010) J Am Soc Nephrol 21(4): 556-63
    › Primary publication · 20167701 (PubMed)